Reported Sunday, Crinetics Presents Phase 2 Data For Atumelnant In CAH Showing 67% Mean Reduction In Androstenedione Levels With 88% Of Participants Achieving Physiologic Glucocorticoid Dose At Week 12

Loading news article.

Reported Sunday, Crinetics Presents Phase 2 Data For Atumelnant In CAH Showing 67% Mean Reduction In Androstenedione Levels With 88% Of Participants Achieving Physiologic Glucocorticoid Dose At Week 12 | WAPE

Reported Sunday, Crinetics Presents Phase 2 Data For Atumelnant In CAH Showing 67% Mean Reduction In Androstenedione Levels With 88% Of Participants Achieving Physiologic Glucocorticoid Dose At Week 12

Article summary

Related companies

Comments —